|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 32140 |
FusionGeneSummary for RPS6KA3_PISD |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: RPS6KA3_PISD | Fusion gene ID: 32140 | Hgene | Tgene | Gene symbol | RPS6KA3 | PISD | Gene ID | 6197 | 23761 |
| Gene name | ribosomal protein S6 kinase A3 | phosphatidylserine decarboxylase | |
| Synonyms | CLS|HU-3|ISPK-1|MAPKAPK1B|MRX19|RSK|RSK2|S6K-alpha3|p90-RSK2|pp90RSK2 | DJ858B16|PSD|PSDC|PSSC|dJ858B16.2 | |
| Cytomap | Xp22.12 | 22q12.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ribosomal protein S6 kinase alpha-3MAP kinase-activated protein kinase 1bMAPK-activated protein kinase 1bMAPKAP kinase 1bMAPKAPK-1bRSK-2S6K-alpha-3insulin-stimulated protein kinase 1p90-RSK 3ribosomal S6 kinase 2ribosomal protein S6 kinase, 90kD | phosphatidylserine decarboxylase proenzyme, mitochondrial | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P51812 | Q9UG56 | |
| Ensembl transtripts involved in fusion gene | ENST00000379565, ENST00000544447, ENST00000379548, ENST00000540702, ENST00000479809, | ENST00000382151, ENST00000266095, ENST00000397500, ENST00000336566, ENST00000439502, ENST00000478893, | |
| Fusion gene scores | * DoF score | 7 X 4 X 5=140 | 3 X 4 X 2=24 |
| # samples | 7 | 4 | |
| ** MAII score | log2(7/140*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/24*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: RPS6KA3 [Title/Abstract] AND PISD [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RPS6KA3 | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 18402937 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | LIHC | TCGA-DD-AACA-02A | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000379565 | ENST00000382151 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379565 | ENST00000266095 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379565 | ENST00000397500 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379565 | ENST00000336566 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379565 | ENST00000439502 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379565 | ENST00000478893 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000382151 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000266095 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000397500 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000336566 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000439502 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000544447 | ENST00000478893 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000382151 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000266095 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000397500 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000336566 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000439502 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000379548 | ENST00000478893 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000382151 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000266095 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000397500 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000336566 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000439502 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| 5CDS-intron | ENST00000540702 | ENST00000478893 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000382151 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000266095 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000397500 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000336566 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000439502 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
| intron-intron | ENST00000479809 | ENST00000478893 | RPS6KA3 | chrX | 20193282 | - | PISD | chr22 | 32028277 | - |
Top |
FusionProtFeatures for RPS6KA3_PISD |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RPS6KA3 | PISD |
| Serine/threonine-protein kinase that acts downstream ofERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenicand stress-induced activation of the transcription factors CREB1,ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 andEIF4B phosphorylation, and mediates cellular proliferation,survival, and differentiation by modulating mTOR signaling andrepressing pro-apoptotic function of BAD and DAPK1. In fibroblast,is required for EGF-stimulated phosphorylation of CREB1 andhistone H3 at 'Ser-10', which results in the subsequenttranscriptional activation of several immediate-early genes. Inresponse to mitogenic stimulation (EGF and PMA), phosphorylatesand activates NR4A1/NUR77 and ETV1/ER81 transcription factors andthe cofactor CREBBP. Upon insulin-derived signal, acts indirectlyon the transcription regulation of several genes byphosphorylating GSK3B at 'Ser-9' and inhibiting its activity.Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation byfacilitating assembly of the preinitiation complex. In response toinsulin, phosphorylates EIF4B, enhancing EIF4B affinity for theEIF3 complex and stimulating cap-dependent translation. Isinvolved in the mTOR nutrient-sensing pathway by directlyphosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2ability to suppress mTOR signaling, and mediates phosphorylationof RPTOR, which regulates mTORC1 activity and may promoterapamycin-sensitive signaling independently of the PI3K/AKTpathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellatecells by phosphorylating CEBPB in response to the hepatotoxincarbon tetrachloride (CCl4). Is involved in cell cycle regulationby phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1Bassociation with 14-3-3 proteins and prevents its translocation tothe nucleus and inhibition of G1 progression. In LPS-stimulateddendritic cells, is involved in TLR4-induced macropinocytosis, andin myeloma cells, acts as effector of FGFR3-mediatedtransformation signaling, after direct phosphorylation at Tyr-529by FGFR3. Negatively regulates EGF-induced MAPK1/3 phosphorylationvia phosphorylation of SOS1. Phosphorylates SOS1 at 'Ser-1134' and'Ser-1161' that create YWHAB and YWHAE binding sites and whichcontribute to the negative regulation of MAPK1/3 phosphorylation(By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630).{ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156,ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362,ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121,ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835,ECO:0000269|PubMed:9770464}. | Catalyzes the formation of phosphatidylethanolamine(PtdEtn) from phosphatidylserine (PtdSer). Plays a central role inphospholipid metabolism and in the interorganelle trafficking ofphosphatidylserine. {ECO:0000255|HAMAP-Rule:MF_03208}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for RPS6KA3_PISD |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for RPS6KA3_PISD |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| RPS6KA3 | PEA15, CREBBP, MAPK1, MAPK3, PDPK1, MAPK14, H2AFX, NEDD4, EIF3C, ATP5J, BARX1, MASP1, SMS, ESR1, YBX1, NFATC1, NFKBIA, TRAF2, MAPT, HSP90AA1, HIST1H3A, HMGN1, FGFR1, DFFA, HSPA8, NAPRT, RASAL1, CSE1L, GDA, NPEPPS, TGM2, SLC9A3R1, RPS6KA1, EGFR, ZMYM5, KIAA1456, TMEM139, HNRNPH1, STIP1, NTRK1, GBA, CDC37, MISP, FGFR2, FYN, TRIM11, IL17RA, WDYHV1, SPRED2, PPP6R2, STRADB, NDEL1, IRGC | PISD | DHX29, DAGLB, BRCA1, KIF15, PTPN1, IFT140, WDR19 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for RPS6KA3_PISD |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | RPS6KA3 | P51812 | DB00945 | Acetylsalicylic acid | Ribosomal protein S6 kinase alpha-3 | small molecule | approved|vet_approved |
Top |
RelatedDiseases for RPS6KA3_PISD |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RPS6KA3 | C0265252 | Coffin-Lowry syndrome | 6 | CTD_human;ORPHANET;UNIPROT |
| Hgene | RPS6KA3 | C0796225 | Mental Retardation, X-Linked 19 | 2 | UNIPROT |
| Hgene | RPS6KA3 | C0005941 | Bone Diseases, Developmental | 1 | CTD_human |
| Hgene | RPS6KA3 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| Hgene | RPS6KA3 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Hgene | RPS6KA3 | C0033922 | Psychomotor Disorders | 1 | CTD_human |
| Hgene | RPS6KA3 | C2239176 | Liver carcinoma | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|